Are 'Designer Babies' Closer Than We Think? Columbia University Advances Human Embryo Gene Editing

Researchers at Columbia University have successfully utilised an advanced genetic modification technique to edit the DNA of early human embryos with unprecedented accuracy. The breakthrough demonstrates a significant reduction in the severe chromosomal damage associated with older gene-editing methods, potentially offering a future pathway to prevent inherited genetic disorders. However, the study has also renewed intense ethical debates within the scientific community regarding the long-term implications of embryonic modification and the potential for selective trait enhancement.

Transition to Base Editing Technology

The research team, led by Columbia University geneticist Dieter Egli, shifted away from traditional CRISPR-Cas9 methods to utilise a newer technique known as base editing. Developed in 2016 by Harvard researchers, base editing chemically alters individual genetic letters by making a small nick in a single DNA strand rather than cutting through both strands. US Scientist Death Case: Missing Nuclear Researcher Melissa Casias Found Dead Nearly a Year After Disappearance in New Mexico.

The study targeted two specific genes in donated fertilised eggs and two-cell embryos: PCSK9, which regulates cholesterol levels and heart disease risk, and HBG, which is involved in fetal haemoglobin production. The molecular tools successfully modified both genes - occasionally simultaneously - without triggering the extensive, catastrophic structural DNA loss observed in the team's previous 2020 CRISPR experiments. While the study has been published online, it is currently undergoing formal peer review for standard publication in a scientific journal. Dr Egli emphasised that despite the technical milestone, the technology is experimental and not ready for clinical application. "We can provide the scientific data, but society must decide how such technology should be used," Egli said.

Technical Persistent Hurdles and 'Mosaicism'

Despite the increased precision, the process encountered biological complications that currently bar it from medical use. In several instances, the editing molecules failed to penetrate every cell uniformly, resulting in "mosaic" embryos where some cells carried the modified sequence, and others retained the original mutation. Outside experts note that mosaicism presents unpredictable medical risks if such an embryo were allowed to develop into a child. Dr Paula Amato, a fertility specialist at Oregon Health & Science University who was not involved in the research, described the data as promising but noted that extensive independent verification remains necessary. Furthermore, bioethicist Ana Iltis of Wake Forest University cautioned that certain long-term harmful side effects might remain completely undetectable until well after birth.

Funding Structures and Clinical Intent

Because United States federal guidelines strictly prohibit the use of public funds for research involving human embryos, the next phases of this study will be supported privately by Nucleus Genomics. The company, which already provides genetic screening for in vitro fertilisation (IVF) embryos, aims to refine the technology to reduce mosaicism and begin testing on more complex embryos containing roughly 100 cells. Nathan Treff, chief clinical officer at Nucleus Genomics and a co-author of the study, noted that the long-term objective is to assist IVF patients by repairing disease-causing mutations in embryos that would otherwise be discarded. "There is still work to do before getting to that point, but this research moves us closer," Treff said.

Ethical Concerns and the Enhancement Debate

The involvement of Nucleus Genomics has drawn scrutiny from bioethicists due to the company's existing commercial profile. The firm currently screens embryos for thousands of medical disorders, but it also provides polygenic risk scoring for complex conditions like diabetes and analyses traits such as height and intelligence. The company previously drew public controversy for a New York subway advertising campaign featuring the slogan "Have your best baby", leading critics to accuse it of commercialising modern eugenics - a claim the company strongly rejects. Many genome-editing pioneers question whether embryo editing is practically necessary, given that pre-implantation genetic testing already allows parents to select mutation-free embryos safely. Who Are the 11 US Scientists Missing or Dead Under ‘Unexplained Circumstances’?

Fyodor Urnov, a prominent geneticist at the University of California, Berkeley, argued that existing screening methods are sufficient and warned that perfecting embryo optimisation tools creates a dangerous dual-use dilemma. Urnov stated that the study inadvertently acts as a foundational blueprint for non-medical genetic enhancements, remarking that the researchers "are really doing is providing the 'baby improvers' with a how-to manual." While Dr Egli believes safe, multi-gene editing may eventually be possible within strict biological limits, the international consensus remains that substantial scientific, safety, and regulatory barriers must be resolved before any clinical implementation can proceed.

(The above story first appeared on LatestLY on Jun 08, 2026 08:52 AM IST. For more news and updates on politics, world, sports, entertainment and lifestyle, log on to our website latestly.com).